The role of Bik in the replication and severity of influenza A virus
Bik 在甲型流感病毒复制和严重程度中的作用
基本信息
- 批准号:10543562
- 负责人:
- 金额:$ 40.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-01 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAntiviral AgentsAppearanceBCL2 geneBIK geneBindingCRISPR/Cas technologyCancer PatientCell physiologyCellsCessation of lifeClinical DataComplexDataDiseaseDisease ManagementDisease ProgressionDoseDrug TargetingEpidemicEpithelial CellsExhibitsFoundationsFrequenciesFutureGeneticGenetic PolymorphismGoalsHumanImpairmentInfectionInfection ControlInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza A virusIntegration Host FactorsLifeLinkLungMediatingModelingMusMutationNucleoproteinsPathway interactionsPeptidesPersonsPneumoniaPredispositionPreventionProcessProteinsPublic HealthPulmonary InflammationPulmonary PathologyRespiratory DiseaseRibonucleoproteinsRiskRisk FactorsRoleSeasonsSeveritiesSeverity of illnessSingle Nucleotide PolymorphismSiteSurvival RateTestingTherapeuticTherapeutic InterventionTimeVaccinationVariantViralViral Drug ResistanceViral GenomeViral Load resultViral ProteinsVirusVirus AssemblyVirus DiseasesVirus ReplicationWild Type Mouseairway epitheliumbronchial epitheliumcohortcostdesigndrug resistance developmenteconomic costflugenetic risk factorgenome integrityhuman diseaseimprovedin vivoindividualized preventioninfluenza A virus nucleoproteininfluenza infectioninhibitormutantnew therapeutic targetnovelnovel strategiespersonalized medicineprotein expressionrecombinant virusrespiratoryrisk variantsmall moleculestemtherapeutically effective
项目摘要
Influenza A virus (IAV) is responsible for seasonal epidemics that results in severe respiratory illness and deaths
worldwide, costing billions of dollars annually in the U.S. alone. Cancer patients are at increased risk of
developing a secondary pneumonia after influenza, which can lead to significant complications. Influenza
infections pose serious challenges due to the lack of effective therapeutic interventions, frequent appearances
of new strains of the virus, and rapid development of drug resistance. New approaches to control infection may
stem from cellular factors or pathways that directly or indirectly interact with viral proteins to enhance or inhibit
virus replication. One of the emerging concepts in the field of IAV is that host cellular factors and pathways are
required for maintaining IAV genome integrity, which is essential for viral replication. Our preliminary data show
that a deficiency of a host cellular protein, Bik, is associated with significant reduction in IAV replication. Our
major findings found that Bik deficiency reduces viral protein levels and viral replication in infected airway
epithelial cells. Furthermore, bik-/- compared to bik+/+ mice exhibit less severe lung inflammation, reduced lung
viral load, and a significant increase in survival rate after infection with IAV. Similarly, a single nucleotide
polymorphism (SNP) in the BIK gene (G→A) that increases Bik expression levels significantly increases viral NP
level and replication in primary normal human bronchial epithelial cells (NHBEs). Furthermore, data from an IAV-
infected human cohort showed that the AA variant of BIK SNP is a risk allele associated with influenza disease
severity. Bik disrupts the interaction of Bcl-2 with IAV-encoded nucleoprotein (NP) and form a Bik/NP complex
that may help assemble viral proteins. The goals of this proposal are to define the role of a host cell protein Bik
in promoting viral replication. Our central hypothesis is that IAV increases host cell Bik protein expression, which
interacts with and disrupts Bcl-2/NP interaction to allow NP to assemble components of viral ribonucleoprotein
(vRNP) and facilitate efficient viral replication. To test this hypothesis, we propose two Specific Aims. Aim 1
identifies the Bik-binding domain of viral NP required for IAV replication. Aim 2 determines whether a
BIK SNP associated with increased Bik expression is a risk factor for influenza disease severity in
humans. Studies are designed to identify the sites of Bik/NP interaction that may serve as potential drug targets
in the future. This study may identify underlying host genetic risk factors contributing to influenza susceptibility
and severity and may have potential implications in regard to targeted prevention and treatment based on
susceptibility factors.
The proposed studies will have significant impacts on the field by dissecting key mechanisms that promote IAV
replication. In the long term, developing peptides or small molecules that disrupt Bik/NP interactions may improve
therapy by reducing IAV replication. Further, this study will identify genetic factors contributing to IAV disease
severity, which can have a broad public health significance.
甲型流感病毒(IAV)是导致严重呼吸道疾病和死亡的季节性流行病的原因
全球范围内,仅在美国每年就花费数十亿美元。癌症患者的风险增加
流感后继发肺炎,可导致严重并发症。流感
由于缺乏有效的治疗干预措施,
新的病毒株,以及抗药性的迅速发展。控制感染的新方法可能
来源于细胞因子或途径,其直接或间接与病毒蛋白相互作用以增强或抑制
病毒复制IAV领域中的新兴概念之一是宿主细胞因子和途径是
这是维持IAV基因组完整性所必需的,这对病毒复制至关重要。我们的初步数据显示
宿主细胞蛋白Bik的缺乏与IAV复制的显著减少有关。我们
一项重要的发现发现是Bik缺乏会降低受感染气道中的病毒蛋白水平和病毒复制
上皮细胞此外,与bik+/+小鼠相比,bik-/-小鼠表现出较不严重的肺部炎症、减少的肺损伤、和/或呼吸道感染。
病毒载量,并与IAV感染后的存活率显着增加。同样,一个核苷酸
增加Bik表达水平的BIK基因中的SNP(G→A)显著增加病毒NP
在原代正常人支气管上皮细胞(NHBE)中的水平和复制。此外,来自IAV的数据-
感染的人类队列显示BIK SNP的AA变体是与流感疾病相关的风险等位基因
严重性。Bik能破坏Bcl-2与IAV编码的核蛋白(NP)的相互作用,形成Bik/NP复合物
可能有助于病毒蛋白的组装。该提案的目标是确定宿主细胞蛋白Bik的作用,
促进病毒复制。我们的中心假设是IAV增加宿主细胞Bik蛋白的表达,
与Bcl-2/NP相互作用并破坏Bcl-2/NP相互作用以允许NP组装病毒核糖核蛋白的组分
(vRNP)并促进有效的病毒复制。为了验证这一假设,我们提出了两个具体目标。要求1
鉴定了IAV复制所需的病毒NP的Bik结合结构域。目标2确定是否
与Bik表达增加相关的BIK SNP是流感病毒疾病严重程度的危险因素,
人类研究旨在确定Bik/NP相互作用的位点,这些位点可能作为潜在的药物靶点
在未来这项研究可能会确定潜在的宿主遗传风险因素,有助于流感易感性
和严重程度,并可能对基于以下方面的针对性预防和治疗产生潜在影响:
易感因素
拟议的研究将通过剖析促进IAV的关键机制对该领域产生重大影响
复制的从长远来看,开发破坏Bik/NP相互作用的肽或小分子可能会改善
减少IAV复制。此外,这项研究将确定遗传因素有助于IAV疾病
严重性,这可能具有广泛的公共卫生意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yohannes Afework Mebratu其他文献
Yohannes Afework Mebratu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yohannes Afework Mebratu', 18)}}的其他基金
The role of Bik in the replication and severity of influenza A virus
Bik 在甲型流感病毒复制和严重程度中的作用
- 批准号:
10701133 - 财政年份:2022
- 资助金额:
$ 40.25万 - 项目类别:
The role of Bik in the replication and severity of influenza A virus
Bik 在甲型流感病毒复制和严重程度中的作用
- 批准号:
10322448 - 财政年份:2021
- 资助金额:
$ 40.25万 - 项目类别:
Bik Promotes Cleavage of Viral Proteins to Enhance Influenza A Virus Infection
Bik 促进病毒蛋白裂解,增强甲型流感病毒感染
- 批准号:
8969925 - 财政年份:2015
- 资助金额:
$ 40.25万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 40.25万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 40.25万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 40.25万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 40.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 40.25万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 40.25万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 40.25万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 40.25万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 40.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 40.25万 - 项目类别:














{{item.name}}会员




